Therapeutic Area: Oncology

Radical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?

Revelant et al.
Frontiers in Immunology
January 2026
immuneAccess
Authors and Affiliates
Alberto Revelant, Francesca Gessoni, Marcella Montico, Raja Dhibi, Giulia Brisotto, Mariateresa Casarotto, Martina Zanchetta, Veronica Paduano, Filippo Sperti, Chiara Evangelista, Fabiana Giordari, Valli De Re, Marco Trovò, Emilio Minatel, Maurizio Mascarin, Agostino Steffan and Elena Muraro

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial

Wang et al.
Journal of Clinical Oncology
January 2026
Authors and Affiliates
Jarey H. Wang, Alexander D. Sherry, Soha Bazyar, Philip Sutera, Noura Radwan, Ryan M. Phillips, Matthew P. Deek, Jiayun Lu, Shirl Dipasquale, Curtiland Deville, Theodore L. DeWeese, Daniel Y. Song, Hao Wang, Robert F. Hobbs, Reem Malek, Sara A. Dudley, Stephen C. Greco, Emmanuel S. Antonarakis, Catherine H. Marshall, Samuel Denmeade, Channing J. Paller, Michael A. Carducci, Kenneth J. Pienta, Orhan K. Oz, Matthew Ramotar, James L. Leenstra, Sean S. Park, Matthew C. Abramowitz, Neil Desai, Alejandro Berlin, Bradley J. Stish, Chad Tang, Phuoc T. Tran, and Ana P. Kiess.

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.

Mayadev et al.
Nature Communications
January 2026
Authors and Affiliates
Jyoti Mayadev, Dmitriy Zamarin, Wei Deng, Heather A. Lankes, Giulio Pesci, Hayeon Kim, Junzo P. Chino, Barbara Banbury, Ned Sherry, Elad Sharon, Sharad A. Ghamande, Catherine Ferguson, Loren Mell, Laura Holman, Cara Mathews, David O’Malley, Alexander Olawaiye, Elizabeth Hopp, Charles Leath III, Larry Copeland, Robert Mannel, Roisin O’Cearbhaill, Carol Aghajanian & Russell J. Schilder

Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.

Miller et al.
BMJ
January 2026
immuneAccess
Authors and Affiliates
Natalie J Miller, Christina Baik, Joel W Neal, Fangdi Sun, Rafael Santana-Davila, Sylvia Lee, Keith D Eaton, Renato G Martins, Cristina Rodriguez, Heather Wakelee, Sukhmani K Padda, Elena Sotillo, Eric Q Konnick, Alex Camai, Tatyana Pisarenko, Viswam S Nair, Crystal Mackall, A McGarry Houghton, Shin-Heng Chiou, Diane Tseng

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial

Izutsu K, et al.
Leukemia Lymphoma
July 2025
Authors and Affiliates
Koji Izutsua, Daigo Akahaneb, Tomomi Toubaic, Toko Saitod, Yuko Mishimae, Tomoaki Fujisakif, Momoko Nishikorig, Takahiro Kumodeh, Youko Suehiroi, Kenji Ishitsukaj, Rebekah Conlonk, Ami Takahashil, Barbara D’Angelo Månssonm, Elena Favarom and Noriko Fukuharan aDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan; bDepartment of Hematology, Tokyo Medical University, Tokyo, Japan; cDepartment of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan; dDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan; eDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; fDepartment of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan; gDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; hDepartment of Hematology and Rheumatology, Kindai University, Osaka, Japan; iDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; jDepartment of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan; kAbbVie, North Chicago, IL, USA; lGenmab, Tokyo, Japan; mGenmab, Copenhagen, Denmark; nDepartment of Hematology, Tohoku University, Sendai, Japan

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.

Wang M, et al
J Clin Oncol
May 2025
Authors and Affiliates
Michael Wang, MD1; David Salek, MD2; David Belada, MD3; Yuqin Song, MD4; Wojciech Jurczak, MD, PhD5†; Brad S. Kahl, MD6; Jonas Paludo, MD7; Michael P. Chu, MD8; Iryna Kryachok, MD9; Laura Fogliatto, MD10; Chan Y. Cheah, DMSc11; Marta Morawska, MD, PhD12,13; Juan-Manuel Sancho, MD14; Yufu Li, MD15; Caterina Patti, MD16; Cecily Forsyth, MD17; Jingyang Zhang, PhD18; Robin Lesley, PhD18; Safaa Ramadan, MD, PhD19; Simon Rule, MD, PhD19; Martin Dreyling, MD, PhD20 for the ECHO investigators* 1Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX, USA; 2Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic; 34th Department of Internal Medicine – Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic; 4Key Laboratory of Carcinogenesis and Translational Research, Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China; 5Pratia MCM Maków, Krakow, Poland; 6Washington University in St Louis, St Louis, Missouri, United States; 7Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; 8Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada; 9Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine; 10Department of Clinical Hematology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; 11Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia and Medical School, University of Western Australia, Perth, Australia; 12Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland; 13Hematology Department, St. John’s Cancer Center, Lublin, Poland; 14Clinical Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain; 15Department of Hematology, Henan Cancer Hospital, Zheng Zhou, China; 16Oncohematology Unit, A.O.O.R. Villa Sofia Cervello, Palermo, Italy; 17Central Coast Haematology, North Gosford, Australia; 18AstraZeneca, South San Francisco, CA, USA; 19AstraZeneca, Cambridge, UK; 20Medizinische Klinik III, Klinikum der Universitaet Munchen, Muenchen, Germany

Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

Aldoss I, et al.
Haematologica
May 2025
Authors and Affiliates
Ibrahim Aldoss,1 Jianying Zhang,2 Kathryn Shimamoto,3 Caner Saygin,3 Marjorie Robbins,4 Vaibhav Agrawal,1 Ahmed Aribi,1 Diren Arda Karaoglu,3 Hoda Pourhassan,1 Paul Koller,1 Haris Ali,1 Amanda Blackmon,1 Salman Otoukesh,1 Karamjeet Sandhu,1 Brian Ball,1 Andrew S. Artz,1 Monzr M. Al Malki,1 Amandeep Salhotra,1 Jose Tinajero,5 Zhaohui Gu,6,7 Ian Lagman,1 Michelle Velasquez,1 Jacqueline Dang,1 Pamela S. Becker,1,8 Michelle Afkhami,9 Lucy Ghoda,6,8,10 Wendy Stock,3 Stephen J. Forman,1 Anthony Stein,1 Guido Marcucci1,6,8 and Vinod Pullarkat1 1Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; 2Department of Biostatistics, City of Hope, Duarte, CA; 3Department of Medicine-Hematology and Oncology, University of Chicago, Chicago, IL; 4Clinical Translational Project Development, City of Hope, Duarte, CA; 5Department of Pharmacy, City of Hope, Duarte, CA; 6Beckman Research Institute, City of Hope, Duarte, CA; 7Computational and Quantitative Medicine, City of Hope, Duarte, CA; 8Hematological Malignancies Translational Science, City of Hope, Duarte, CA; 9Department of Pathology, City of Hope, Duarte, CA and 10Department of Research Business Operations, City of Hope, Duarte, CA, USA